Efficacy and safety combination therapy with simvastatin and gemfibrozil for combined hyperlipidemia

Objective:To evaluate the efficacy and safety of combination therapy with simvastatin and gemfibrozil in patients with combine hyperlipidemia.Methods:110 patients with combined hyperlipidemia were randomly assigned to receive 20mg simvastatin(n=33)or 900mg gemfibrozil(n=32)or a combination of 10mg simvastatin+450mg gemfibrozil(n=35)for 6 months.Lipid index and side effects were assessed.Results:Combination treatment more effective in normalizing lipid than any monotherapy.Serum TC,LDL-C,and TG were reduce,While HDL-C significantly increased(all P0.01).The successful rate of LDL-C,TC,and TG control in the combination therapy group were 41%,49%,and 57% respectively,with overall success rate(all three together)of 46%,which was superior to either drug given as monotherapy(all P0.01).All treatment were well tolerated with no increase in side effects for combination therapy versus monotherapy.Conclusions:The results of this study demonstrated that combination therapy with low-dose simvastatin(10mg/d)and gemfibrozil(450mg/d)is more effective than monotherapy in patients with combined hyperlipidemia,and is generally safe and well toleraled.